Metabolic Latest News Archive
Heritability of BMI was significantly higher in children living in high-risk obesogenic environments compared with those living in low-risk environments.
High variability of fasting blood glucose and total cholesterol levels, systolic blood pressure, and BMI may be an independent predictor of cardiovascular events.
For this analysis, the authors used follow-up data from all 7020 patients included in the EMPA-REG OUTCOME trial to estimate the effect of empagliflozin on all-cause mortality vs placebo over the duration of a patient's lifetime.
Atopic dermatitis was not found to be an independent risk factor for cardiometabolic disease in this meta-analysis.
Triglyceride-lowering variants in the lipoprotein lipase pathway are independently associated with protection from coronary artery disease and type 2 diabetes.
Investigators used data from the National Health Interview Survey and follow-up mortality data to estimate trends and disparities in CVD.
The risk for cardiovascular events in patients with type 2 diabetes without manifest cardiovascular disease is primarily related to the severity of atherosclerosis.
While certain biomarkers are associated with eGFR decline in patients with type 2 diabetes, their predictive power is low.
A clinical trial assessing canagliflozin (Invokana; Janssen) as an addition to standard-of-care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has been stopped early after meeting its pre-specified efficacy criteria.
Results showed the overall safety profile of linagliptin in study patients, including adults with kidney disease, was consistent with previous data.
Approximately 12,000 patients took part in the CAMELLIA-TIMI 61 trial in which participants were randomized to either lorcaserin HCl 10mg twice daily or placebo.
Investigators examined the association between hypoglycemia and cardiovascular outcomes and death.
Investigators examined the relationship between the use of β-blockers and incidence of hypoglycemia and risk for mortality in hospitalized patients with diabetes.
Investigators conducted a meta-analysis to compare the efficacy of SGLT2i, DPP-4i, and GLP-1 agonists for reducing cardiovascular outcomes.
The ITCA 650, a small titanium osmotic mini-pump, provides a subcutaneous infusion of exenatide over 3 or 6 months.
Regardless of presence of preexisting cardiovascular disease, SGLT2 inhibitors were associated with lower risk for death and heart failure.
To understand the mechanism underlying the benefit of fenofibrate on vascular complications in patients with type 2 diabetes, investigators assessed carotid intima thickness as a marker of subclinical atherosclerosis.
Investigators sought to determine whether methylglyoxal levels are associated with cardiovascular disease in type 2 diabetes.
Patients with remitted bipolar disorder and emotional hyper-reactivity also have significantly higher levels of low-grade inflammation, hypertension, and impaired glucose metabolism, indicating a higher risk for cardiometabolic dysfunction.
Investigators examined the frequency of cardiovascular vs noncardiovascular deaths in individuals who developed prediabetes that did not progress to diabetes.
Investigators examined the effect of testosterone replacement therapy on metabolic syndrome and vascular function in obese males with hypogonadism.
Younger patients treated with antipsychotics after experiencing a first episode of psychosis are at an increased risk for metabolic syndrome and cardiovascular disease.
Further studies are needed to assess whether beta-blockers are effective in reducing mortality and coronary events in patients with diabetes receiving optimal medical treatment.
Patients with type 2 diabetes at risk for heart failure are particularly likely to benefit from treatment with canagliflozin.
The American Diabetes Association has updated its Clinical Standards of Medical Care guidelines for identifying and managing cardiovascular risk factors in diabetes.
Investigators sought to determine the association between serum phospholipid fatty acid composition, low-grade inflammation, and glycemic control in patients with T2D.
Researchers tested whether semen quality and reproductive function could be a marker of general health in men.
ACP responds to criticism from the ADA, the Endocrine Society, the AACE, and the AADE of guidance that clinicians should aim to achieve an HbA1c level between 7% and 8% in most people with type 2 diabetes.
The FDA has approved an update to the prescribing information for Tresiba to include cardiovascular outcomes and severe hypoglycemia study data.
Statins were associated with a reduction in mortality but there was no significant difference in the composite end point with fenofibrates alone or in combination with statins.
In people with obesity and type 2 diabetes, a meal schedule that includes a high-energy breakfast promotes weight loss, improves diabetes, and decreases the need for insulin.
The American Diabetes Association has responded with "deep" concern to recent hemoglobin A1c target guidance authored by the American College of Physicians.
T2D may play a protective role against the development of aortic diseases through structural changes in the aortic wall.
The expanded use of TIMI Risk Score for Secondary Prevention in patients with T2D may be helpful to predict risk for CV events accurately.
Glucagon-like peptide-1 receptor agonists can reduce major adverse cardiovascular events in patients with type 2 diabetes.
The FDA has approved semaglutide injection for the treatment of type 2 diabetes in adults.
Weight gain associated with insulin therapy is not associated with adverse cardiovascular outcomes in people with type 2 diabetes.
Evolocumab may decrease the risk for adverse cardiovascular events in patients with and without diabetes.
Initiation of insulin therapy in patients with type 2 diabetes was associated to inactivity and weight gain.
Patients with psoriasis have high rates of cardiometabolic comorbidities.
Patients with diabetes had a higher rate of readmission to hospitals compared with patients without diabetes.
Tentative FDA approval has been granted to Merck's follow-on biologic basal insulin injection, Lusduna Nexvue.
Metformin therapy in type 1 diabetes may improved cardiovascular disease risk management.
Novo Nordisk submitted an application to the FDA with data on the cardiovascular safety of an insulin degludec.
American Diabetes Association presented a study that Canagliflozin could possibly decrease cardiovascular stress in older patients with type 2 diabetes.
Two studies found that extended-release naltrexone/bupropion did not increase cardiovascular risks for patients with type 2 diabetes.
Kidney and eye events in type 2 diabetes were reduced with more intensive glucose control.
A meta-analysis was conducted to examine concerns surrounding direct oral anticoagulant therapy in patients with extreme high or low body weight.
Glucagon-like peptide-1 receptor agonist therapy was associated with lower risk for acute MI, stroke, and all-cause mortality.
Frequent hot flashes in younger women were linked to endothelial function, providing more insight into the cardiovascular disease risk status of patients.
Overweight or obese patients with type 2 diabetes mellitus are more likely to show severe and progressive brain function and cognition abnormalities.
A large, initial reduction in hemoglobin A1c (HbA1c) and achievement of low HbA1c levels 6 months after metformin initiation lowered the risk for cardiovascular events and death in patients with type 2 diabetes.
The majority of patients with diabetes requiring hospitalization for severe hypoglycemia were patients with type 2 diabetes.
Patients with type 1 diabetes admitted for acute myocardial infarction had higher mortality rates compared with patients with type 2 diabetes.
Avocado consumption most affected LDL, HDL, and total cholesterol, triglycerides, and phospholipids.
Compared with New York counties without trans fatty acid restrictions, those with restrictions showed a significantly greater decline in combined myocardial infarction and stroke events.
Patients with HbA1c levels had lower 7-year incidence of major adverse cardiac and cerebrovascular events compared with patients with higher HbA1c levels.
Study results emphasize the importance of identifying optimal treatment regimens for patients with serious mental illness.
Higher BMI was associated with lower all-cause and cardiac mortality in adults with congenital heart disease, even after adjusting for age, defect complexity, cyanosis, and objective exercise capacity.
Patients with obesity and type 2 diabetes were exposed to 3 different aspirin formulations.
In a postmarket trial of more than 7000 adults, empagliflozin was superior to placebo for reduction of cardiovascular death.
According to this risk assessment tool, the majority of US adults are considered high risk for prediabetes, though confirmation is required through medical visit and blood glucose test.
Changes in quantity and attenuation of abdominal fat affect changes in incident CVD and metabolic risk factors.
There was a hazard ratio of 1.87 per 1-ng/dL increase of free thyroxine for patients with an increased risk of sudden cardiac death due to higher free thyroxine levels.
An AHA panel recommended developing guidelines on adequate sleep and suggestions on how to include sleep disorder screenings in routine health care and public health settings.
Information technology interventions were successful in studies evaluating changes in diet, tobacco and alcohol use, and physical activity.
The group who developed diabetes earlier had less favorable left ventricular ejection fraction, 4-chamber longitudinal peak strain, and circumferential peak strain.
African-American women in particular experienced more rapid progression in metabolic syndrome severity during pre- and peri-menopausal periods compared to post-menopausal period.
LEADER trial results demonstrated that liraglutide lowered first occurrence of death from cardiovascular causes in patients with type 2 diabetes.
Heart failure is a particularly powerful predictor of mortality in patients who have both coronary heart disease and type 2 diabetes.
The obese group compared with the group in 5th to 24th BMI percentiles had higher hazard ratios for death from coronary heart disease, stroke, sudden death, and total cardiovascular causes.
Liraglutide decreased desirability of high-fat, high-caloric foods, which could lead to the drug being used as weight loss therapy.
In patients who were at high risk for cardiovascular disease, 25% of those from Puerto Rican and Dominican backgrounds used statins and less than half used aspirin.
Individuals who used active modes of transport, walking, cycling, as well as mixing walking and cycling with public transit had significantly lower BMI and percentage body fat compared with sedentary car users.
Ideal BMI, lack of smoking, and ideal fasting glucose were the 3 cardiovascular health factors most strongly associated with greater processing speed performance.
In metabolomic profiling study, statins were found to affect more extensive lipid changes beyond low-density lipoprotein cholesterol.
Apixaban Associated With Lower Risk for Stroke Than Aspirin in Patients With AF and Low-Risk Stroke Classification
The anticoagulant apixaban was found to increase life expectancy at a higher rate than aspirin in patients with low risk for stroke.
Replacing Saturated Fats and Sugary Carbohydrates With Unsaturated Fats Reduces Risk of Coronary Heart Disease
Replacing saturated fats and sugary carbohydrates with unsaturated fats reduces the risk of coronary heart disease.
Interrupting long periods of sedentary behavior with short walks could reduce cardiometabolic risk in children.
Sitagliptin did not affect rates of cardiovascular complications or heart failure in high-risk patients with type 2 diabetes.
The Cardiology Advisor Articles
- Cardiac Troponin Elevation Predicts Major Adverse Events Even Without Specific Diagnosis
- Does Pre-Existing PH Affect Outcomes in Transcatheter Mitral Valve Repair?
- How Has the Medicaid Expansion Affected Patients Hospitalized With Acute MI?
- Macitentan Not Superior to Placebo for Improving Exercise Capacity in Eisenmenger Syndrome
- Association Between Statins and Depression Likely Mediated by Confounding
- ASH Develops Practice Guidelines for Venous Thromboembolism
- Tetralogy of Fallot: Long-Term Outcomes After Surgical Repair
- Cardiac Troponin Elevation Predicts Major Adverse Events Even Without Specific Diagnosis
- Stethoscopes in ICU Show High Levels of Bacterial Contamination
- Catheter Ablation Superior to Drug Therapy for Atrial Fibrillation in Heart Failure
- Researchers Identify Golden Ratio Between Pulmonary Pressure Components in PAH
- FDA: Potential Increased Mortality With Paclitaxel-Coated Balloons, Stents for PAD
- Inhaled Dry Powder Formulation of Treprostinil Well Tolerated in PAH
- Elevated Myocardial T1 Associated With Increased Septal Angle in PAH
- Pulmonary Hypertension Intensive Care Options Depend on Treatment Goals